Two Sigma Securities LLC Has $3.59 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Two Sigma Securities increased its Regeneron position by 407.6% in the second quarter, ending with 5,761 shares valued at approximately $3.59 million. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Regeneron reported stronger-than-expected quarterly results, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year. The company also announced a quarterly dividend of $0.94 per share.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $800.36, but the company faces risks from mixed melanoma-trial results and related securities-fraud litigation notices.

Two Sigma Securities LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 407.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,761 shares of the biopharmaceutical company's stock after buying an additional 4,626 shares during the period. Two Sigma Securities LLC's holdings in Regeneron Pharmaceuticals were worth $3,592,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Orbimed Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth $11,358,000. Lockheed Martin Investment Management Co. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $2,702,000. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. National Pension Service increased its stake in shares of Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock valued at $278,636,000 after buying an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $10,472,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Wall Street Analyst Weigh In

A number of equities analysts recently commented on REGN shares. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Leerink Partners boosted their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research report on Monday, August 17th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research report on Monday, May 18th. Fifteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $800.36.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $794.19 on Monday. The company has a market cap of $81.77 billion, a P/E ratio of 19.63, a PEG ratio of 1.35 and a beta of 0.22. The stock has a 50 day simple moving average of $717.52 and a two-hundred day simple moving average of $717.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $12.81 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 over the last ninety days. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source